发布求助
文献互助 智能选刊 最新文献

Nature Reviews Clinical Oncology最新文献

筛选
英文 中文
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress 作者更正：美国抗癌疗法的高昂成本：挑战、机遇与进步
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-30 DOI: 10.1038/s41571-024-00958-z
Shelley A. Jazowski, Rahul K. Nayak, Stacie B. Dusetzina
{"title":"Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress","authors":"Shelley A. Jazowski, Rahul K. Nayak, Stacie B. Dusetzina","doi":"10.1038/s41571-024-00958-z","DOIUrl":"10.1038/s41571-024-00958-z","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 12","pages":"903-903"},"PeriodicalIF":81.1,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41571-024-00958-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142536890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cadonilimab is effective and safe in recurrent cervical cancer 卡多尼单抗对复发性宫颈癌有效且安全
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-25 DOI: 10.1038/s41571-024-00962-3
Diana Romero
{"title":"Cadonilimab is effective and safe in recurrent cervical cancer","authors":"Diana Romero","doi":"10.1038/s41571-024-00962-3","DOIUrl":"10.1038/s41571-024-00962-3","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 1","pages":"2-2"},"PeriodicalIF":81.1,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142489804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’ 回复 "NALIRIFOX在转移性胰腺癌一线治疗中的应用：NAPOLI 3以外的证据
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-25 DOI: 10.1038/s41571-024-00953-4
Christopher Nevala-Plagemann, Thierry Conroy, Ignacio Garrido-Laguna
{"title":"Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’","authors":"Christopher Nevala-Plagemann, Thierry Conroy, Ignacio Garrido-Laguna","doi":"10.1038/s41571-024-00953-4","DOIUrl":"10.1038/s41571-024-00953-4","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 12","pages":"902-902"},"PeriodicalIF":81.1,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41571-024-00953-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3 NALIRIFOX 在转移性胰腺癌一线治疗中的应用：NAPOLI 3 之外的证据
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-25 DOI: 10.1038/s41571-024-00952-5
Zev A. Wainberg, Eileen M. O’Reilly
{"title":"NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3","authors":"Zev A. Wainberg, Eileen M. O’Reilly","doi":"10.1038/s41571-024-00952-5","DOIUrl":"10.1038/s41571-024-00952-5","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 12","pages":"900-901"},"PeriodicalIF":81.1,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41571-024-00952-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lack of benefit from extended lymphadenectomy in muscle-invasive bladder cancer 肌肉浸润性膀胱癌的扩大淋巴结切除术缺乏益处
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-23 DOI: 10.1038/s41571-024-00961-4
Diana Romero
{"title":"Lack of benefit from extended lymphadenectomy in muscle-invasive bladder cancer","authors":"Diana Romero","doi":"10.1038/s41571-024-00961-4","DOIUrl":"10.1038/s41571-024-00961-4","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 12","pages":"838-838"},"PeriodicalIF":81.1,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The TOPGEAR trial — is chemoradiotherapy no longer a component of multidisciplinary care for gastric cancer? TOPGEAR 试验--化放疗是否不再是胃癌多学科治疗的组成部分？
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-21 DOI: 10.1038/s41571-024-00960-5
Brian Badgwell
{"title":"The TOPGEAR trial — is chemoradiotherapy no longer a component of multidisciplinary care for gastric cancer?","authors":"Brian Badgwell","doi":"10.1038/s41571-024-00960-5","DOIUrl":"10.1038/s41571-024-00960-5","url":null,"abstract":"Adjuvant chemoradiotherapy has a proven survival benefit for patients undergoing upfront resection of gastric cancer compared with surgery alone. Now, data from the TOPGEAR trial demonstrate that adding radiotherapy to standard-of-care perioperative chemotherapy offers no additional survival benefit. I discuss the implications for treatment and future research.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 1","pages":"4-5"},"PeriodicalIF":81.1,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142451853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MRI-based stratification reduces the risk of overdiagnosis of prostate cancer 基于磁共振成像的分层可降低前列腺癌过度诊断的风险
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-16 DOI: 10.1038/s41571-024-00957-0
Peter Sidaway
{"title":"MRI-based stratification reduces the risk of overdiagnosis of prostate cancer","authors":"Peter Sidaway","doi":"10.1038/s41571-024-00957-0","DOIUrl":"10.1038/s41571-024-00957-0","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 12","pages":"838-838"},"PeriodicalIF":81.1,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142439733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author Correction: Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response 作者更正：针对dMMR和pMMR结直肠癌的新辅助免疫疗法：治疗策略和反应的假定生物标志物
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-07 DOI: 10.1038/s41571-024-00955-2
Christopher J. M. Williams, Allyson M. Peddle, Pashtoon M. Kasi, Jenny F. Seligmann, Campbell S. Roxburgh, Gary W. Middleton, Sabine Tejpar
{"title":"Author Correction: Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response","authors":"Christopher J. M. Williams, Allyson M. Peddle, Pashtoon M. Kasi, Jenny F. Seligmann, Campbell S. Roxburgh, Gary W. Middleton, Sabine Tejpar","doi":"10.1038/s41571-024-00955-2","DOIUrl":"10.1038/s41571-024-00955-2","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 12","pages":"903-903"},"PeriodicalIF":81.1,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41571-024-00955-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142383729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The high costs of anticancer therapies in the USA: challenges, opportunities and progress 美国抗癌疗法的高昂成本：挑战、机遇与进步
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-04 DOI: 10.1038/s41571-024-00948-1
Shelley A. Jazowski, Rahul K. Nayak, Stacie B. Dusetzina
{"title":"The high costs of anticancer therapies in the USA: challenges, opportunities and progress","authors":"Shelley A. Jazowski, Rahul K. Nayak, Stacie B. Dusetzina","doi":"10.1038/s41571-024-00948-1","DOIUrl":"10.1038/s41571-024-00948-1","url":null,"abstract":"The USA spent $99 billion on orally administered and clinician-administered anticancer therapies (excluding supportive care) in 2023 and spending is projected to increase to $180 billion by 2028. This increased spending on anticancer therapies largely reflects the high launch prices of novel therapeutics and increases in the prices of existing products, even in the absence of new evidence of clinical benefit or changes in use. Consequently, high prices have impeded Americans’ access to and affordability of necessary anticancer therapies and thus increased their risk of cost-related non-adherence, cancer recurrence and mortality. To address the rising prices and concerns regarding Americans’ spending on anticancer therapies, state and federal governments have, over the past decade, enacted legislation that caps out-of-pocket spending, expands subsidies and requires drug price negotiations. In this Perspective, we summarize US policies aimed to lower the costs of anticancer therapies, discuss the implications of such reforms and propose additional solutions needed to reduce costs and increase value. The high cost of anticancer drugs is a problem worldwide that impairs access to treatment. These high costs are particularly notable in the USA, where the prices of cancer drugs are often double those of the same drugs in other economically developed countries. In this Perspective, the authors describe the origins and scale of this problem, and summarize the various state-level and federal-level interventions designed to reduce the costs of anticancer drugs, and thus improve access for patients.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 12","pages":"888-899"},"PeriodicalIF":81.1,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142374140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reflecting on the past 20 years in oncology 回顾过去 20 年的肿瘤学历程
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-01 DOI: 10.1038/s41571-024-00950-7
{"title":"Reflecting on the past 20 years in oncology","authors":"","doi":"10.1038/s41571-024-00950-7","DOIUrl":"10.1038/s41571-024-00950-7","url":null,"abstract":"The November 2024 issue of Nature Reviews Clinical Oncology marks the 20th anniversary of the journal. Here, we reflect on the role of the journal during a time in which the clinical oncology community has witnessed many important changes.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 11","pages":"763-763"},"PeriodicalIF":81.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41571-024-00950-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信